Dopamine function in cigarette smokers: An [18]-DOPA PET study

Neuropsychopharmacology

Volumn 39, Issue 10, 2014, Pages 2397-2404

  Bloomfield, Michael A P ^a,b   Pepper, Fiona ^a,b   Egerton, Alice ^a,b   Demjaha, Arsime ^a,b   Tomasi, Gianpaolo ^a   Mouchlianitis, Elias ^a   Maximen, Levi ^a   Veronese, Mattia ^b   Turkheimer, Federico ^b   Selvaraj, Sudhakar ^a   Howes, Oliver D ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; NICOTINE; DOPA; DOPAMINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BRAIN REGION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE SYNTHESIS CAPACITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; METABOLIC PARAMETERS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TOBACCO DEPENDENCE; ANALOGS AND DERIVATIVES; METABOLISM; QUESTIONNAIRE; SCINTISCANNING;

ADULT; CASE-CONTROL STUDIES; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SMOKING; SURVEYS AND QUESTIONNAIRES; TOBACCO USE DISORDER;

EID: 84906324416     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.87     Document Type: Article

References (61)

1. Balfour DJ, Wright AE, Benwell ME, Birrell CE (2000). The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113: 73-83
2. Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006). Cannabisinduced psychosis-like experiences are associated with high schizotypy. Psychopathology 39: 175-178
3. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004). The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54: 65-71
4. Benowitz NL, Henningfield JE (1994). Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 331: 123-125
5. Benowitz NL, Jacob P 3rd, Jones RT, Rosenberg J (1982). Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 221: 368-372
6. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2013). Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms. Biol Psychiatry 75: 470-478
7. Bock KW, Köhle C (2004). Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters. Drug Metab Rev 36: 595-615
8. Boyes BE, Cumming P, Martin WR, McGeer EG (1986). Determination of plasma [18F]-6-fluorodopa during positron emission tomography: Elimination and metabolism in carbidopa treated subjects. Life Sci 39: 2243-2252
9. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P et al (2004). Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161: 1211-1218
10. Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA (2009). Dopaminergic activity in depressed smokers: A positron emission tomography study. Synapse 63: 681-689
11. Chiuccariello L, Guranda M, Rusjan PM, Wilson AA, Zawertailo L, Houle S et al (2013). Presentation of smoking-Associated cues does not elicit dopamine release after one-hour smoking abstinence: A [11C]-()-PHNO PET study. PLoS One 8: E60382
12. Clarke PB, Pert A (1985). Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348: 355-358
13. Connolly GN, Alpert HR, Wayne GF, Koh H (2007). Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997-2005. Tob Control 16: E5
14. Cumming P, Leger GC, Kuwabara H, Gjedde A (1993). Pharmacokinetics of plasma 6-[18F]fluoro-L-3, 4-dihydroxyphenylalanine ([18F]Fdopa) in humans. J Cereb Blood Flow Metab 13: 668-675
15. Cumming P, Boyes BE, Martin WR, Adam M, Grierson J, Ruth T et al (1987). The metabolism of [18F]6-fluoro-L-3, 4-dihydroxyphenylalanine in the hooded rat. J Neurochem 48: 601-608
16. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr (1999). A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31: 76-86
17. Dierker LC, Avenevoli S, Stolar M, Merikangas KR (2002). Smoking and depression: An examination of mechanisms of comorbidity. Am J Psychiatry 159: 947-953
18. Dluzen DE, Anderson LI (1997). Estrogen differentially modulates nicotine-evoked dopamine release from the striatum of male and female rats. Neurosci Lett 230: 140-142
19. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD (2010). The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 50: 524-531
20. Ezzati M, Lopez AD (2003). Estimates of global mortality attributable to smoking in 2000. Lancet 362: 847-852
21. First MB SR, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCIDCV). American Psychiatric Press: Washington, DC
22. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R et al (1996a). Inhibition of monoamine oxidase B in the brains of smokers. Nature 379: 733-736
23. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C et al (1996b). Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93: 14065-14069
24. Gallezot JD, Kloczynski T, Weinzimmer D, Labaree D, Zheng MQ, Lim K et al (2013). Imaging nicotine-And amphetamine-induced dopamine release in Rhesus monkeys with [11C]PHNO vs [11C]raclopride PET. Neuropsychopharmacology 39: 866-874
25. Geracioti TD Jr, West SA, Baker DG, Hill KK, Ekhator NN, Wortman MD et al (1999). Low CSF concentration of a dopamine metabolite in tobacco smokers. Am J Psychiatry 156: 130-132
26. Guttman M, Leger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM et al (1993). Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 8: 298-304
27. Grenhoff J, Aston-Jones G, Svensson TH (1986). Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128: 351-358
28. Haber SN (2003). The primate basal ganglia: Parallel and integrative networks. J Chem Neuroanat 26: 317-330
29. Heinz A, Siessmeier T, Wrase J, Buchholz HG, Gründer G, Kumakura Y et al (2005). Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: A combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 162: 1515-1520
30. Hietala J, Syvälahti E, Vilkman H, Vuorio K, Räkkölä inen V, Bergman J et al (1999). Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 35: 41-50
31. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P et al (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13-20
32. Hughes JR, Keely J, Naud S (2004). Shape of the relapse curve and long-Term abstinence among untreated smokers. Addiction 99: 29-38
33. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC (1993). Smoking and major depression. A causal analysis. Arch Gen Psychiatry 50: 36-43
34. Koob GF (1992). Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654: 171-191
35. Kumakura Y, Cumming P (2009). PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches. Neuroscientist 15: 635-650
36. Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E et al (2002). Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 52: 753-763
37. Lautala P, Ethell BT, Taskinen J, Burchell B (2000). The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28: 1385-1389
38. Le Foll B, Guranda M, Wilson AA, Houle S, Rusjan PM, Wing VC et al (2013). Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [11C]-()-PHNO PET Study in Humans. Neuropsychopharmacology 39: 415-424
39. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED et al (1998). Depression and self-medication with nicotine: The modifying influence of the dopamine D4 receptor gene. Health Psychol 17: 56-62
40. Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004). Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29: 257-268
41. Martinez D, Slifstein M, Broft A, Mawlawi T, Hwang DR, Huang YY et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamineinduced dopamine release in the functional subdivisions of the striatum. J Cerebr Blood F Met 23: 285-300
42. Menossi HS, Goudriaan AE, de Azevedo-Marques Périco C, Nicastri S, de Andrade AG, D'Elia G et al (2013). Neural bases of pharmacological treatment of nicotine dependence-insights from functional brain imaging: A systematic review. CNS Drugs 27: 921-941
43. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM (2007). The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse 61: 637-645
44. Office for National Statistics (2013). Opinions and Lifestyle Survey, Smoking Habits Amongst Adults, 2012. Office for National Statistics: London, United Kingdom
45. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (1997). Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390: 401-404
46. Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257
47. Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M et al (2000). High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 157: 632-634
48. Sossi V, Holden JE, de la Fuente-Fernandez R, Ruth TJ, Stoessl AJ. (2003). Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab. 23: 301-309
49. Stolerman IP, Mirza NR, Shoaib M (1995). Nicotine psychopharmacology: Addiction, cognition and neuroadaptation. Med Res Rev 15: 47-72
50. Studholme C, Hill DL, Hawkes DJ (1996). Automated 3-D registration of MR and CT images of the head. Med Image Anal 1: 163-175
51. Tai YF, Hoshi R, Brignell CM, Cohen L, Brooks DJ, Curran HV et al (2011). Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): An 18F-dopa PET study. Neuropsychopharmacology 36: 735-743
52. Thomsen G, Knudsen GM, Jensen PS, Ziebell M, Holst KK, Asenbaum S et al (2013). No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res 3: 39
53. Tsukada H, Miyasato K, Harada N, Nishiyama S, Fukumoto D, Kakiuchi T (2005). Nicotine modulates dopamine synthesis rate as determined by L-[beta-11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain. Synapse 57: 120-122
54. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ (1999). Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 19: 1189-1208
55. Villard PH, Herber R, Sérée EM, Attolini L, Magdalou J, Lacarelle B (1998). Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice. Pharmacol Toxicol 82: 74-79
56. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011). Addiction: Beyond dopamine reward circuitry. Proc Natl Acad Sci USA 108: 15037-15042
57. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D et al (2012). Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17: 918-925
58. West R, McNeill A, Raw M (2000). Smoking cessation guidelines for health professionals: An update. Health Education Authority. Thorax 55: 987-999
59. Wu JC, Bell K, Najafi A, Widmark C, Keator D, Tang C et al (1997). Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 17: 402-409
60. Zhang H, Sulzer D (2004). Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci 7: 581-582
61. Zhang L, Kendler KS, Chen X (2006). The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct 2: 28